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Phenytoin is a commonly prescribed antiepileptic drug. Due to its saturation (zero-order) pharmacokinetics,
phenytoin carries a special risk of dose-related toxicity that is an important issue in emergency medicine.
The purpose of this cross-sectional case-series study was to investigate the causes, symptoms, misdiagnoses,
and outcomes of acute phenytoin intoxication. It was based on a retrospective chart review of 30 inpatients
(mean age, 41.6 ± 22.8 years) with 36 episodes of acute phenytoin intoxication at our university hospital
in the past 13 years. The average initial serum phenytoin level was 47.3 ±  9.7 µg/mL (range, 27.9–
70.4 µg/mL). Excessive self-medication, misunderstanding of the prescription order, and probable drug
interaction were the three leading causes of acute phenytoin intoxication. Unsteady gait, dizziness/vertigo,
nausea/vomiting, general weakness, and drowsiness were the most common presenting symptoms. The
tentative diagnostic accuracy was 67%. The most common initial misdiagnosis was brainstem or cerebellum
stroke (14%). The clinical course in all patients was uneventful under temporary withdrawal of phenytoin
and supportive care. We concluded that acute phenytoin intoxication was relatively under-diagnosed in
the emergency service. Although acute phenytoin intoxication causes no mortality and has a good outcome,
the unsteady gait increases the risk of injuries caused by falls. The management of acute phenytoin
intoxication includes temporary withdrawal of phenytoin and supportive care.
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Phenytoin is a commonly prescribed antiepileptic drug. It
is also used for the treatment of paroxysmal kinesigenic
dyskinesia [1], myotonia [2], Isaacs’ syndrome [3], and
neuropathic pain [4,5]. Phenytoin is hydroxylated and
converted to the para isomer of 5-hydroxy-phenyl-5-
phenylhydantoin (p-HPPH) in the liver and is excreted as
the glucuronide conjugate of p-HPPH in the urine. The
metabolic conversion to p-HPPH is a saturable process. The
point at which saturation occurs is unpredictable and varies
among individuals. Once saturated, the serum phenytoin
concentration rises in a curvilinear manner. This is why
small increments in dose can cause a large increase in the
serum phenytoin level in many patients [6]. Phenytoin
intoxication is one reason why persons with epilepsy visit
the emergency department. The narrow therapeutic index,
the wide inter-individual variability in the rate of phenytoin
metabolism and clearance, and the saturation (zero-order)
pharmacokinetics of phenytoin are responsible for the
observed dose-related toxicity. The purpose of this retro-
spective case-series study was to investigate the causes,
symptoms, misdiagnoses, and outcomes of acute phenytoin
intoxication at a university hospital in southern Taiwan.
PATIENTS AND METHODS
This case-series study was a retrospective chart review
of inpatients. A computer-assisted search of medical re-
cords identified patients diagnosed with acute phenytoin
intoxication who had been admitted to the departments of
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adult and pediatric neurology in our hospital in the past
13 years. Demographic data, phenytoin dose, and serum
phenytoin levels were obtained from the medical records.
All patients had documented serum phenytoin levels of
more than 20 µg/mL, clinical evidence of toxicity at pre-
sentation, and improvement of clinical symptoms and
signs after the serum phenytoin level declined to around
the therapeutic level.
Serum phenytoin level was measured using a fluo-
rescence polarization immunoassay (Abbott Laboratories
Inc, Abbott Park, IL, USA). A dilution protocol was used if
the serum phenytoin level was more than 40 µg/mL.
Serum phenytoin levels were monitored daily following
temporary discontinuation of phenytoin in 12 adults with
12 episodes. The average daily rate of decline of serum
phenytoin level was derived by subtracting the serum
phenytoin level nearest to 20 µg/mL from the serum
phenytoin level at presentation and then dividing by the
time interval (expressed in days).
RESULTS
There were 30 patients in this series: three children, four
adolescents, and 23 adults (mean age, 41.6 ±  22.8 years;
range, 1–79 years). Six patients had had two episodes of
phenytoin intoxication and 24 had each had a single episode,
giving a total of 36 episodes of phenytoin intoxication.
Twenty-two patients took phenytoin as monotherapy, seven
took it with one other anticonvulsant (phenobarbital in
three patients, carbamazepine in one, vigabatrin in one,
lamotrigine in one, and primidone in one), and one patient
took phenytoin, carbamazepine, and sodium valproate at
the same time. The indications for phenytoin treatment
were idiopathic epilepsy (8/30, 27%), symptomatic epilepsy
(21/30, 70%), and neuropathic pain (1/30, 3%).
The leading cause of phenytoin intoxication was ex-
cessive self-medication (14/36 episodes, 39%; Table 1) for
one of several reasons: recurrence of seizures after stop-
ping or reducing phenytoin dose by themselves; unsatis-
factory seizure control with the prescribed dosage; the
other concomitant anticonvulsant had been used up and
an increased phenytoin dose was used as temporary
monotherapy; or to prevent seizures when fatigued or
sleep-deprived.
Six episodes (17%) in six patients were probably
secondary to drug interaction. Four of these patients were
reported to be intoxicated with phenytoin after taking or
injecting some common-cold medications. One patient
showed phenytoin toxicity after stopping the co-
administered primidone. Another patient took phenytoin,
prochlorperazine, propranolol, and clonazepam at the same
time.
Five episodes (14%) in four patients were caused by
misunderstanding the prescription order. Three of these
episodes occurred in two patients, documented as mental-
ly subnormal, who handled medication by themselves.
Caregivers were responsible for the other two episodes in
another two patients.
Iatrogenic causes of intoxication accounted for four
episodes (11%) in the present study. All were caused by
excessive intravenous supplementary (“booster”) loading
for a single seizure. One patient took phenytoin irregular-
ly and suffered from occasional seizures, but she did not
mention her poor compliance to the doctor. She was then
asked to take a higher dose of phenytoin regularly and
suffered from intoxication thereafter.
The time interval between phenytoin dose increments and
the appearance of clinical symptoms was variable and ranged
from several hours to 3 days. It was within hours for the patient
who attempted suicide by taking a large amount of pheny-
toin and for patients intoxicated iatrogenically by excessive
intravenous supplementary loading for a single seizure. The
time interval was usually 1 day if the increment was 300–500
mg/day and 1–3 days if the increment was 200 mg/day.
Our patients presented with a great variety of symptoms
(Table 2). Unsteady gait was the most common (78%). Four
patients suffered from falling caused by unsteady gait, two
without obvious injury but two with an ear laceration wound
and an eye ecchymosis, respectively. The frequency of the
most common clinical symptoms and the initial serum
phenytoin level is shown in Figure 1. The less frequent
symptoms, such as headache, confusion, blurred vision, and
slurred speech, were noted when the initial serum phenytoin
Table 1. Causes of acute phenytoin intoxication in 36
episodes
Causes of intoxication Frequency
Suicide attempt 1
Improved compliance 1
Iatrogenic 4
Misunderstanding of the 5
prescription order
Undetermined 5
Probable drug interaction 6
Excessive self-medication 14
(patient-initiated dose increase)
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level was more than 40 µg/mL. We used the duration of
hospital stay as an index of severity of phenytoin intoxica-
tion and found no significant correlation between the initial
serum phenytoin level and the duration of hospital stay.
An accurate initial diagnosis of phenytoin intoxication
was made in 24 (67%) of 36 episodes (Table 3). Five episodes
(14%) in four patients were initially diagnosed as brainstem
or cerebellar stroke. Two of these four patients had a history
of cerebrovascular disease and post-stroke epilepsy and
were suspected of having recurrent brainstem or cerebellar
stroke. The other two patients (3 episodes) were a 40-year-
old with a medical history of diabetes mellitus and hyper-
tension and a patient with a medical history of diabetes
mellitus who had two episodes of intoxication at 67 and 71
years of age.
The mean duration of phenytoin treatment was 10.9 ±
11.8 years (range, 0.3–44 years). The average initial serum
phenytoin level in the emergency service was 47.3 ±  9.7
µg/mL (range, 27.9–70.4 µg/mL). The average daily rate of
decline of serum phenytoin level was 8.6 ±  1.4 µg/mL
(range, 6.3–11.1 µg/mL), which was significantly correlated
with the patient’s regular phenytoin dosage (r = 0.68, p =
0.02; Figure 2) but not with the initial serum phenytoin level
(r = 0.46, p = 0.13). This might explain why the duration of
hospital stay was not significantly correlated with the initial
serum phenytoin level. One patient who was intoxicated by
excessive self-medication presented with an initial phenytoin
level of 53 µg/mL, which rose to 63.7 µg/mL the next day
and declined gradually. This was most likely due to delayed
absorption of phenytoin in the gastrointestinal tract. Two
patients had one seizure episode each before restarting
Table 2. Clinical symptoms of acute phenytoin intoxication
in 36 episodes
Symptom Frequency*
Hand tremor 1
Abdominal pain 1
Slurred speech 2
Blurred vision 4
Confusion 5
Headache 8
Drowsiness 10
General weakness 14
Nausea/vomiting 15
Dizziness/vertigo 17
Unsteady gait 28
*Many patients had more than one symptom at presentation.
Figure 1. Frequency of the most common clinical symptoms and the initial serum phenytoin level.
Table 3. Initial diagnosis for the 36 episodes of acute
phenytoin intoxication
Initial diagnosis Frequency
Subarachnoid hemorrhage 1
Complex partial seizure status 1
Degenerative disease 1
Deferred 4
Brainstem or cerebellar stroke 5
Phenytoin intoxication 24
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phenytoin treatment. Their phenytoin levels at the time of
seizure recurrence were 24.1 and 16 µg/mL, respectively.
We retrospectively documented an average of three
episodes of hospitalization due to acute phenytoin intoxi-
cation per year in our hospital over a 13-year period. Vital
signs were stable at presentation and through the hospital
course in every patient. The mean hospital stay was 6.7 ±
2.7 days (range, 3–14 days). None of these patients had
hemodynamic compromise or respiratory distress requiring
intensive care. All patients were treated by temporarily
discontinuing phenytoin and providing supportive care.
There was no mortality in these 30 patients.
DISCUSSION
The most common cause of acute phenytoin intoxication in
our series was excessive self-medication. Patient-caused
intoxication is preventable if patients are adequately edu-
cated about their medication. Due to the pharmacokinetic
features of phenytoin, it is suggested that physicians who
treat patients with epilepsy have both low-dose phenytoin
(e.g. 30 mg) and 100 mg phenytoin available. Increments of
phenytoin must be given gradually, especially around the
lower limit of the therapeutic range (10 µg/mL). Since phe-
nytoin toxicity may occur before a steady state is reached, it
may be prudent to monitor the patient for toxic symptoms
and to consider a serum phenytoin level check-up several
days (e.g. 3–5 days) after dosage initiation or adjustment
[7]. Iatrogenic intoxication can also be reduced by imple-
menting a didactic and case-based program to educate
physicians about phenytoin pharmacokinetics and the
loading, maintenance, adjustment, and monitoring of
phenytoin therapy [7].
To avoid misunderstanding of the prescription order,
mentally subnormal patients should not be allowed to
administer their own medications. Also, caregivers,
especially those whose native language is not the same as
that of the prescribing physician and the patient, should be
given a clear translation of the order in a language in which
they are fluent. Patients with uncertain compliance may be
admitted for supervision before increasing their phenytoin
dosage. Medications commonly used for the common cold
have not been reported to increase serum phenytoin levels
significantly or acutely [8]. Since the cold medications used
by the four patients were not available, their cause–effect
relationship cannot be determined. Drug interactions
between phenytoin and primidone, prochlorperazine,
propranolol, and clonazepam have been reported [6].
Unsteady gait was the most common presenting
symptom in this study, similar to a previous report [9]. Four
patients suffered from falls. We suggest that bed rest or
assisted ambulation is mandatory during the acute
intoxication period. Under-diagnosis of phenytoin
intoxication was not uncommon (12/36, 33%). The acute
onset and spectrum of clinical presentations, especially
the most common symptoms of unsteady gait, dizziness/
vertigo, and nausea/vomiting, may raise a suspicion of
brainstem or cerebellar stroke. This is why the five episodes
in our elderly subjects with risk factors for vascular disease
were initially diagnosed as brainstem or cerebellar stroke.
Delayed recognition of acute phenytoin intoxication in this
subgroup usually leads to unnecessary or inappropriate
medical intervention and concomitant deterioration of
existing symptoms/signs by continuing phenytoin
treatment. Presentation with relatively uncommon symp-
toms, an incomplete medical history, and failure to no-
tice gum hyperplasia or nystagmus are the leading reasons
for under-diagnosis of phenytoin intoxication. Hand trem-
or and other movement disorders are rare manifestations
of phenytoin intoxication [10,11]. A complete history,
inspection for gum hyperplasia in patients with brainstem
or cerebellar symptoms and signs, and knowledge of the
full spectrum of clinical presentations of acute phenytoin
intoxication would improve diagnostic accuracy.
The observed decline in serum phenytoin levels was
8.6 ± 1.4 µg/mL/day (range, 6.3–11.1 µg/mL/day) in 12
adults. In clinical practice, it is important to estimate how
long phenytoin should be temporarily withdrawn and when
phenytoin therapy might safely be restarted with a limited
Figure 2. Correlation between regular phenytoin dosage and average
daily rate of decline of serum phenytoin level in 12 adult phenytoin-
intoxicated patients.
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number of blood samples. Several case reports have shown
graphically the serial serum phenytoin levels after discon-
tinuation of phenytoin in acutely intoxicated patients with-
out offering practical guidelines for the timing of phenytoin
monitoring and the reinstitution of phenytoin [12–16]. The
serum phenytoin half-life is concentration-dependent and
previous studies have demonstrated a considerable individual
variation in Michaelis-Menten parameters (maximum rate of
metabolism and phenytoin level at which metabolic rate will
be one-half the maximum) [17,18]. Age, ethnicity, supervening
illness, or interacting drugs have significant influence on the
pharmacokinetics of phenytoin. It is therefore difficult to
accurately predict the rate of decline of serum phenytoin levels
in patients with acute phenytoin intoxication using a simple
equation. This is also why there is still a lack of simple practical
guidelines for monitoring phenytoin and reinstitution of
phenytoin therapy. As our data were retrospectively assessed
and there was no standardized blood sampling scheme for
most patients, the observed rate of decline derived from a
small number of patients (n = 12) with a wide age range (21–
81 years) may not work well in clinical practice. A prospective
study in newly diagnosed phenytoin-intoxicated patients is
necessary to validate the clinical usefulness of a crude estimate
of phenytoin decline by 8.6 ± 1.4 µg/mL/day. Perhaps a better
strategy would be to measure phenytoin concentrations at
presentation and 2 or 3 days later, and to consider that, at high
phenytoin concentrations, the decline of phenytoin is nearly
linear [17]. At a concentration of approximately 25 µg/mL, the
rate of elimination is greatly increased, which results in a
relatively rapid fall in the serum phenytoin concentration [12].
There were no circulatory collapses or deaths in our series.
None of the patients needed intensive care. The outcomes of
our patients were as good as those of patients in previous
reports [19–21]. Acute intoxication by oral phenytoin rare-
ly causes death [22,23]. The circulatory collapse caused by
intravenous phenytoin may be due to a rapid rise in serum
phenytoin level or to a toxic solvent, such as propylene gly-
col [19–21]. We conclude that acute phenytoin intoxication
was relatively under-diagnosed in the emergency service. Al-
though acute phenytoin intoxication causes no mortality
and has a good outcome, the unsteady gait increases the risk
of injuries caused by falls. The management of acute phe-
nytoin intoxication includes temporary withdrawal of
phenytoin and supportive care.
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